Novartis (NVS) announced trial results Tuesday that showed one in four metastatic breast cancer patients remained progression-free for four or more years following treatment with Kisqali plus endocrine therapy.

The data showed that the patients had a median progression-free survival of 6.8 years, Novartis said.

The results were from a pooled, post-hoc exploratory analysis of first-line patients in the Monaleesa trials, Novartis said.

Shares of the company were up 2% in recent Tuesday trading.

Price: 132.93, Change: +2.76, Percent Change: +2.12